Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation

被引：0
|
作者：
Jonassen, I. [1 ]
Hoeg-Jensen, T. [1 ]
Havelund, S. [1 ]
Ribel, U. [1 ]
机构：
[1] Novo Nordisk AS, Malov, Denmark
来源：
JOURNAL OF PEPTIDE SCIENCE | 2010年 / 16卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [1] New ultra-long acting basal insulin: Insulin degludec
    Simo, Rafael
    AVANCES EN DIABETOLOGIA, 2013, 29 (01): : 4 - 11
  • [2] Clinical use of the co-formulation of insulin degludec and insulin aspart
    Kumar, A.
    Awata, T.
    Bain, S. C.
    Ceriello, A.
    Fulcher, G. R.
    Unnikrishnan, A. G.
    Arechavaleta, R.
    Gonzalez-Galvez, G.
    Hirose, T.
    Home, P. D.
    Kaku, K.
    Litwak, L.
    Madsbad, S.
    Pinget, M.
    Mehta, R.
    Mithal, A.
    Tambascia, M.
    Tibaldi, J.
    Christiansen, J. S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (08) : 657 - 667
  • [3] Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
    Kalra, Sanjay
    DIABETES THERAPY, 2014, 5 (01) : 65 - 72
  • [4] Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
    Sanjay Kalra
    Diabetes Therapy, 2014, 5 : 65 - 72
  • [5] Insulin aspart: A new rapid-acting insulin analog
    Setter, SM
    Corbett, CF
    Campbell, RK
    White, JR
    ANNALS OF PHARMACOTHERAPY, 2000, 34 (12) : 1423 - 1431
  • [6] Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart
    Heinemann, L
    Weyer, C
    Rauhaus, M
    Heinrichs, S
    Heise, T
    DIABETES CARE, 1998, 21 (11) : 1910 - 1914
  • [7] PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF AN ULTRA-CONCENTRATED, RAPID-ACTING INSULIN ASPART FORMULATION
    Pieber, T.
    Gerring, D.
    Howell, S.
    Jezek, J.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A139 - A139
  • [8] Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
    Svend Havelund
    Ulla Ribel
    František Hubálek
    Thomas Hoeg-Jensen
    Per-Olof Wahlund
    Ib Jonassen
    Pharmaceutical Research, 2015, 32 : 2250 - 2258
  • [9] Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
    Havelund, Svend
    Ribel, Ulla
    Hubalek, Frantisek
    Hoeg-Jensen, Thomas
    Wahlund, Per-Olof
    Jonassen, Ib
    PHARMACEUTICAL RESEARCH, 2015, 32 (07) : 2250 - 2258
  • [10] Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
    Dedov, I. I.
    Shestakova, M. V.
    DIABETES MELLITUS, 2014, 17 (04): : 108 - 119
12345